Internationally Standardized Testing - LabPMM - Multiparametric Flow Cytometry

Multiparametric Flow Cytometry Panels

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.

Multiparametric Flow Cytometry Panels

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.

EXPLORE MFC PANELS ⟶

FUTURE DEVELOPMENT SERVICES

Multiparametric Flow Cytometry Panels

Multiple Myeloma Minimum Residual Disease by Multiparametric Flow Cytometry (MM MRD by MFC)

(CD38, CD138, CD27, CD56, CD28, CD45, CD19, CD20, CD117, CD81, cytoplasmic Kappa, and cytoplasmic Lambda)

B-Acute lymphoblastic leukemia (B-ALL) Minimal Residual Disease Panel by Multiparametric Flow Cytometry (B-ALL MRD by MFC)

(CD123, CD45, CD19, CD34, CD38, CD10, CD22, CD58, CD66C, CD9, CD13, CD33, and CD20)

Custom Immunophenotyping panels for drug development

Markers based on client need

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.

CLINICAL LAB SERVICES

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

Leveraging Standardized MRD Assays to Guide CLL Treatment

wmm2024-01-25T10:44:11-08:00January 25th, 2024|2024 Publications, Featured Publications, Publications|

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

Invivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases|

ALL RELATED ARTICLES ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

January 25th, 2024 Leveraging Standardized MRD Assays to Guide CLL Treatment

March 23rd, 2023 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Multiparametric Flow Cytometry Panels

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing – streamlining clinical trials for accurate results comparisons.

Multiparametric Flow Cytometry Panels

Hematolymphoid Screening Panel – MFC

AML MRD Assay – MFC

CLL MRD Assay – MFC

FUTURE DEVELOPMENT SERVICES

Multiparametric Flow Cytometry Panels

Multiple Myeloma Minimum Residual Disease by Multiparametric Flow Cytometry (MM MRD by MFC)

(CD38, CD138, CD27, CD56, CD28, CD45, CD19, CD20, CD117, CD81, cytoplasmic Kappa, and cytoplasmic Lambda)

B-Acute lymphoblastic leukemia (B-ALL) Minimal Residual Disease Panel by Multiparametric Flow Cytometry (B-ALL MRD by MFC)

(CD123, CD45, CD19, CD34, CD38, CD10, CD22, CD58, CD66C, CD9, CD13, CD33, and CD20)

Custom Immunophenotyping panels for drug development

Markers based on client need

CLINICAL LAB SERVICES

Related Articles

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Leveraging Standardized MRD Assays to Guide CLL Treatment

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.